AVR

Analyst Note: Anteris Technologies Global Corp. (AVR)

Date: 2026-06-20 Current Price: $9.78

1. Structural Readiness

State: Context-Only Conservative Entry: — Current Price: $9.78 Extension: — ATR at Breakout: — ATR Current: 5.6% (High) Pivot Strength: —

Structural Assessment:

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Exposure: None Named Assessment: As of this date, there is no named macro or secular thesis attached to AVR. This is a tactical, setup-led name. Conviction must be derived strictly from the quality of the technical setup (the forming coil) and the fundamental business progress recorded in the evidence base. No external macro themes should be invented to support the thesis; the investment case rests entirely on the company's execution of its clinical and regulatory milestones and the subsequent market reaction to those events.

3. Business Overview

Company: Anteris Technologies Global Corp. Industry: Healthcare / Medical Devices Business Model: Anteris is a medical device company focused on the development and commercialization of the DurAVR® Transcatheter Heart Valve (THV) System. The system is designed to treat aortic stenosis, a life-threatening condition involving the narrowing of the aortic valve. The company operates on a model of advancing proprietary technology through clinical trials to secure regulatory approval (FDA PMA and CE Mark) for commercialization.

Key Business Milestones (As of 2026-06-20):

• Clinical Trial Progress: The PARADIGM Trial, a prospective, randomized, controlled multicenter international study, is active. Recruitment commenced in Europe in October 2025, and the trial received FDA Investigational Device Exemption (IDE) approval in November 2025.
• Reimbursement & Enrollment: In April 2026, the company secured U.S. Medicare reimbursement eligibility for the PARADIGM Trial under a CMS national coverage policy. This milestone supported the activation of initial U.S. sites, with the first patients enrolled and treated in May 2026.
• Regulatory Strategy: The PARADIGM Trial is designed to provide the primary clinical evidence required for the FDA to grant Premarket Approval (PMA) for the DurAVR® THV System in the United States.
• Competitive Landscape: Management states that no competitor currently has a single-piece tissue TAVR commercially available or has publicly disclosed such a product in development. Primary competitors include Edwards Lifesciences Corporation and Medtronic.
• Market Opportunity: Management cites FMI data projecting the global market opportunity for TAVR in severe aortic stenosis to reach $9.9 billion and $2.5 billion for ViV procedures by 2028.
• Current Status: As of December 2025, more than 130 patients have been implanted with the DurAVR® THV worldwide.

4. Archetype and Conviction Stack

Archetype: Growth Leader / Clinical Catalyst Rationale: The company fits the "Growth Leader" archetype in the context of a pre-commercialization medical device firm. The value driver is the successful execution of the PARADIGM Trial and the subsequent regulatory approval, which would unlock the commercial market. The "single-piece tissue" differentiation is a key structural implication for potential market share capture against incumbents Edwards and Medtronic.

Conviction Stack:

• Thesis Strength: Low (Tactical/Setup-led; no macro tailwinds).
• Evidence Quality: High. The evidence base (E1–E14) is robust, citing specific dates, regulatory approvals (IDE, CMS), and enrollment numbers. The progression from European initiation (Oct 2025) to U.S. enrollment (May 2026) demonstrates execution.
• Structural Quality: Moderate. The forming coil indicates a base is being built, but the lack of a confirmed breakout means the market has not yet priced in the full success of the trial.
• Rerating Potential: High, contingent on the trial data readout and PMA approval. The path from $9.78 to a commercial valuation depends entirely on the transition from "clinical trial participant" to "commercial product."

5. Invalidation, Strengthening, and Gaps

Invalidation Triggers:

• Fundamental: Failure to enroll patients at the newly activated U.S. sites, or negative safety signals emerging from the 130+ implants already performed.

Strengthening Triggers:

• Technical: A confirmed breakout above the forming coil resistance with volume expansion.
• Fundamental: Positive interim data readouts from the PARADIGM Trial or accelerated regulatory feedback from the FDA regarding the PMA pathway.

Evidence Gaps:

• Financials: The evidence block lacks specific financial data (revenue, cash burn, runway) as of June 2026. The company is pre-revenue (clinical stage), so the "financial spine" is missing from the provided evidence.
• Trial Timeline: While enrollment has started, the specific timeline for the primary endpoint data readout is not explicitly stated in the provided evidence, creating uncertainty on the immediate catalyst horizon.
• Commercialization Costs: No data on the projected cost of commercialization post-approval.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: 1. PARADIGM Trial active with U.S. sites activated and first patients enrolled as of May 2026. 2. CMS national coverage policy secured in April 2026, removing a major reimbursement barrier. 3. Unique single-piece tissue design with no direct competitor product in development. Key risks: 1. Clinical trial failure or safety signals could halt PMA approval. 2. High ATR (5.6%) indicates elevated volatility and potential for sharp downside if sentiment shifts. 3. Lack of revenue and reliance on capital raises for pre-commercialization operations. Sizing hint: Position size should reflect the binary nature of the clinical catalyst and the high volatility; treat as a satellite holding. Expected path: Management expects the PARADIGM Trial data to provide the evidence for FDA PMA approval; successful data readout should lead to commercial launch discussions. Expected horizon: 12 to 24 months for the trial data readout and regulatory decision.